ATE257708T1 - Kombinationen enthaltend vx478, zidovudin und 3tc zur behandlung von hiv - Google Patents
Kombinationen enthaltend vx478, zidovudin und 3tc zur behandlung von hivInfo
- Publication number
- ATE257708T1 ATE257708T1 AT97928263T AT97928263T ATE257708T1 AT E257708 T1 ATE257708 T1 AT E257708T1 AT 97928263 T AT97928263 T AT 97928263T AT 97928263 T AT97928263 T AT 97928263T AT E257708 T1 ATE257708 T1 AT E257708T1
- Authority
- AT
- Austria
- Prior art keywords
- zidovudine
- hiv
- treatment
- combinations containing
- combinations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2054396P | 1996-06-25 | 1996-06-25 | |
| US2102796P | 1996-07-02 | 1996-07-02 | |
| GBGB9614022.3A GB9614022D0 (en) | 1996-07-04 | 1996-07-04 | Antiviral therapeutic combinations |
| PCT/EP1997/003247 WO1997049411A1 (en) | 1996-06-25 | 1997-06-23 | Combinations comprising vx478, zidovudine, ftc and/or 3tc for use in the treatment of hiv |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE257708T1 true ATE257708T1 (de) | 2004-01-15 |
Family
ID=27268358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97928263T ATE257708T1 (de) | 1996-06-25 | 1997-06-23 | Kombinationen enthaltend vx478, zidovudin und 3tc zur behandlung von hiv |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US6544961B1 (de) |
| EP (1) | EP0938321B1 (de) |
| JP (1) | JP2000515852A (de) |
| KR (1) | KR20000022226A (de) |
| CN (1) | CN1228026A (de) |
| AP (1) | AP9801419A0 (de) |
| AT (1) | ATE257708T1 (de) |
| AU (1) | AU727983B2 (de) |
| BR (1) | BR9709939A (de) |
| CA (1) | CA2258956A1 (de) |
| CO (1) | CO4900074A1 (de) |
| CZ (1) | CZ429498A3 (de) |
| DE (1) | DE69727240T2 (de) |
| EA (1) | EA001517B1 (de) |
| ES (1) | ES2213217T3 (de) |
| HU (1) | HUP9903249A3 (de) |
| ID (1) | ID19490A (de) |
| IL (1) | IL127351A0 (de) |
| IS (1) | IS4915A (de) |
| NO (1) | NO986034L (de) |
| NZ (1) | NZ333099A (de) |
| PL (1) | PL330747A1 (de) |
| TR (1) | TR199802704T2 (de) |
| TW (1) | TW469132B (de) |
| WO (1) | WO1997049411A1 (de) |
| YU (1) | YU58398A (de) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY115461A (en) | 1995-03-30 | 2003-06-30 | Wellcome Found | Synergistic combinations of zidovudine, 1592u89 and 3tc |
| US6875773B1 (en) | 1998-05-29 | 2005-04-05 | Ben M. Dunn | Combination therapy for treatment of FIV infection |
| CA2374198A1 (en) * | 1998-05-29 | 1999-12-02 | Maki Arai | Combination therapy for treatment of fiv infection |
| GB0011903D0 (en) * | 2000-05-18 | 2000-07-05 | Astrazeneca Ab | Combination chemotherapy |
| BRPI0606119B8 (pt) * | 2005-02-01 | 2021-05-25 | Troikaa Pharmaceuticals Ltd | preparações injetáveis de diclofenaco e seus sais farmaceuticamente aceitáveis |
| ES2279707B1 (es) * | 2005-11-10 | 2008-06-01 | Combino Pharm, S.L. | Formulaciones orales que comprenden 3'-azidonucleosidos. |
| US8168662B1 (en) | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8168661B2 (en) * | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8173686B2 (en) | 2006-11-06 | 2012-05-08 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8178564B2 (en) * | 2006-11-06 | 2012-05-15 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US20110033528A1 (en) * | 2009-08-05 | 2011-02-10 | Poniard Pharmaceuticals, Inc. | Stabilized picoplatin oral dosage form |
| TW200916094A (en) * | 2007-06-27 | 2009-04-16 | Poniard Pharmaceuticals Inc | Stabilized picoplatin dosage form |
| US20100260832A1 (en) * | 2007-06-27 | 2010-10-14 | Poniard Pharmaceuticals, Inc. | Combination therapy for ovarian cancer |
| JP2010533714A (ja) * | 2007-07-16 | 2010-10-28 | ポニアード ファーマシューティカルズ， インコーポレイテッド | ピコプラチンのための経口製剤 |
| CA2715329A1 (en) * | 2008-02-08 | 2009-08-13 | Poniard Pharmaceuticals, Inc. | Picoplatin and amrubicin to treat lung cancer |
| CA2967453C (en) * | 2010-01-27 | 2018-07-17 | Viiv Healthcare Company | Combinations for use in the inhibition of hiv-1 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4724232A (en) * | 1985-03-16 | 1988-02-09 | Burroughs Wellcome Co. | Treatment of human viral infections |
| US5047407A (en) | 1989-02-08 | 1991-09-10 | Iaf Biochem International, Inc. | 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties |
| MY104575A (en) | 1989-12-22 | 1994-04-30 | The Wellcome Foundation Ltd | Therapeutic nucleosides. |
| US5204466A (en) | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
| GB9009861D0 (en) | 1990-05-02 | 1990-06-27 | Glaxo Group Ltd | Chemical compounds |
| IL100502A (en) | 1991-01-03 | 1995-12-08 | Iaf Biochem Int | PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (- |
| NZ250842A (en) * | 1991-02-22 | 1996-03-26 | Univ Emory | Resolution of a racemic mixture of nucleoside enantiomers such as 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (ftc) |
| GB9104740D0 (en) * | 1991-03-06 | 1991-04-17 | Wellcome Found | Antiviral nucleoside combination |
| DK0513917T4 (da) | 1991-05-16 | 2001-06-25 | Glaxo Group Ltd | Antivirale kombinationer indeholdende nukleosidanaloger |
| GB9111902D0 (en) | 1991-06-03 | 1991-07-24 | Glaxo Group Ltd | Chemical compounds |
| GB9307013D0 (en) * | 1993-04-02 | 1993-05-26 | Wellcome Found | Therapeutic combinations |
| DE69321845T2 (de) | 1992-08-25 | 1999-04-29 | Searle & Co | Hydroxyethylaminosulfonamide verwendbar als inhibitoren retroviraler proteasen |
| IS2334B (is) * | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl próteasi hemjari af nýjum flokki súlfonamíða |
| US5723490A (en) * | 1992-09-08 | 1998-03-03 | Vertex Pharmaceuticals Incorporated | THF-containing sulfonamide inhibitors of aspartyl protease |
| UA49803C2 (uk) | 1994-06-03 | 2002-10-15 | Дж.Д. Сьорль Енд Ко | Спосіб лікування ретровірусних інфекцій |
| GB9503850D0 (en) | 1995-02-25 | 1995-04-19 | Glaxo Group Ltd | Medicaments |
| US5869461A (en) | 1995-03-16 | 1999-02-09 | Yale University | Reducing toxicity of L-nucleosides with D-nucleosides |
| MY115461A (en) | 1995-03-30 | 2003-06-30 | Wellcome Found | Synergistic combinations of zidovudine, 1592u89 and 3tc |
| US5646180A (en) | 1995-12-05 | 1997-07-08 | Vertex Pharmaceuticals Incorporated | Treatment of the CNS effects of HIV |
| TW536403B (en) | 1997-03-24 | 2003-06-11 | Glaxo Group Ltd | An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy |
-
1997
- 1997-06-23 CN CN97197357A patent/CN1228026A/zh active Pending
- 1997-06-23 HU HU9903249A patent/HUP9903249A3/hu unknown
- 1997-06-23 IL IL12735197A patent/IL127351A0/xx unknown
- 1997-06-23 ES ES97928263T patent/ES2213217T3/es not_active Expired - Lifetime
- 1997-06-23 WO PCT/EP1997/003247 patent/WO1997049411A1/en active Search and Examination
- 1997-06-23 NZ NZ333099A patent/NZ333099A/en unknown
- 1997-06-23 CO CO97034781A patent/CO4900074A1/es unknown
- 1997-06-23 KR KR1019980710646A patent/KR20000022226A/ko not_active Application Discontinuation
- 1997-06-23 AP APAP/P/1998/001419A patent/AP9801419A0/en unknown
- 1997-06-23 PL PL97330747A patent/PL330747A1/xx unknown
- 1997-06-23 ID IDP972147A patent/ID19490A/id unknown
- 1997-06-23 JP JP10502320A patent/JP2000515852A/ja not_active Ceased
- 1997-06-23 BR BR9709939A patent/BR9709939A/pt unknown
- 1997-06-23 CA CA002258956A patent/CA2258956A1/en not_active Abandoned
- 1997-06-23 EA EA199801045A patent/EA001517B1/ru not_active IP Right Cessation
- 1997-06-23 DE DE69727240T patent/DE69727240T2/de not_active Expired - Fee Related
- 1997-06-23 AT AT97928263T patent/ATE257708T1/de not_active IP Right Cessation
- 1997-06-23 TR TR1998/02704T patent/TR199802704T2/xx unknown
- 1997-06-23 EP EP97928263A patent/EP0938321B1/de not_active Expired - Lifetime
- 1997-06-23 AU AU32627/97A patent/AU727983B2/en not_active Ceased
- 1997-06-23 CZ CZ984294A patent/CZ429498A3/cs unknown
- 1997-06-23 US US09/202,660 patent/US6544961B1/en not_active Expired - Fee Related
- 1997-08-05 TW TW086111193A patent/TW469132B/zh active
-
1998
- 1998-11-30 IS IS4915A patent/IS4915A/is unknown
- 1998-12-16 YU YU58398A patent/YU58398A/sr unknown
- 1998-12-22 NO NO986034A patent/NO986034L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BR9709939A (pt) | 1999-08-10 |
| CA2258956A1 (en) | 1997-12-31 |
| DE69727240D1 (de) | 2004-02-19 |
| YU58398A (en) | 1999-11-22 |
| EA199801045A1 (ru) | 1999-08-26 |
| CN1228026A (zh) | 1999-09-08 |
| NO986034D0 (no) | 1998-12-22 |
| EA001517B1 (ru) | 2001-04-23 |
| TR199802704T2 (xx) | 1999-03-22 |
| AU3262797A (en) | 1998-01-14 |
| WO1997049411A1 (en) | 1997-12-31 |
| IS4915A (is) | 1998-11-30 |
| HUP9903249A2 (hu) | 2000-10-28 |
| NZ333099A (en) | 2000-06-23 |
| EP0938321A1 (de) | 1999-09-01 |
| KR20000022226A (ko) | 2000-04-25 |
| IL127351A0 (en) | 1999-10-28 |
| US6544961B1 (en) | 2003-04-08 |
| DE69727240T2 (de) | 2004-11-25 |
| CZ429498A3 (cs) | 1999-06-16 |
| ES2213217T3 (es) | 2004-08-16 |
| AP9801419A0 (en) | 1998-12-31 |
| HUP9903249A3 (en) | 2001-04-28 |
| PL330747A1 (en) | 1999-05-24 |
| NO986034L (no) | 1999-02-23 |
| AU727983B2 (en) | 2001-01-04 |
| CO4900074A1 (es) | 2000-03-27 |
| ID19490A (id) | 1998-07-16 |
| EP0938321B1 (de) | 2004-01-14 |
| JP2000515852A (ja) | 2000-11-28 |
| TW469132B (en) | 2001-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69739758D1 (de) | Vakzine zur behandlung von lymphomen und leukämie | |
| DE60023128D1 (de) | Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen | |
| DE69812681D1 (de) | Unsubstituierte polydiallylaminen zur behandlung von hypercholesterolemia | |
| ATE296634T1 (de) | (s,s)-reboxetin zur behandlung von fibromyalgie und anderen somatoformen störungen | |
| DE69739303D1 (de) | Vorrichtung zur thermischen behandlung von gewebe | |
| DE69806579T2 (de) | Anlage zur behandlung von nahrungsmitteln | |
| ATE257708T1 (de) | Kombinationen enthaltend vx478, zidovudin und 3tc zur behandlung von hiv | |
| DE69835031D1 (de) | Neue anti-hiv immunogene (toxoide), herstellungsverfahren und verwendungen zur behandlung und vorbeugung von aids | |
| DE69715482T2 (de) | Herstellung von 1,1,1,3,3-Pentachlorbutan und von 1,1,1,3,3-Pentafluorbutan | |
| DE69711311T2 (de) | Vorrichtung zur thermischen Behandlung von Gewebe | |
| DE69019345T2 (de) | Zusammensetzung zur behandlung von samen. | |
| DE3850433D1 (de) | Allergiebehandlung und Zusammensetzung dafür. | |
| DE69807466D1 (de) | Triptolid-derivate nützlich zur behandlung von autoimmunkrankheiten | |
| ATE347372T1 (de) | Vakzine zur behandlung von mycosen | |
| DE29718503U1 (de) | Gerät zur Behandlung von Tinitus und Hyperakusis | |
| DE69825319D1 (de) | Präparat zur vorbeugung und behandlung von entzündungen | |
| DE69519602D1 (de) | Kugelförmige Aktivkohle zur Behandlung von Hämorrhoiden | |
| DE69834937D1 (de) | Antibiotika zur behandlung von magengeschwuren | |
| DE69926485D1 (de) | Behandlung von durchblasgasen | |
| DE69814993D1 (de) | Quasi-azeotrope Mischungen auf Basis von 1,1,1,3,3,-Pentafluorobutan, Methylene Chloride und Methanol zur Behandlung von festen Oberflächen | |
| DE69806062T2 (de) | Kombinationstherapie zur behandlung von aids | |
| DE59905059D1 (de) | Verfahren zur Herstellung von Hydroxyethylcyclohexanen und Hydroxyethylpiperidinen | |
| DE69718168T2 (de) | Zusammensetzungen enthaltend vx478, zidovudine und 159u89 für die verwendung in der behandlung von hiv | |
| DE69802300D1 (de) | Behandlung von schädlichen flüssigkeiten | |
| ATE284706T1 (de) | Neue verbesserte formulierung zur behandlung von thromboembolismus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |